Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.

Slides:



Advertisements
Similar presentations
Resource requirements for reaching the treatment goals under PEPFAR XV International AIDS Conference Bangkok July 15, 2004 Owen Smith, Abt Associates Inc.
Advertisements

Are You Smarter Than A 5th Grader? TRU Price of Tobacco and Initiation Trivia.
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA,
Brazzaville, Congo 5-7 March 2014
Assessment of PEPFAR’s Impact on Selected Health System Parameters in Sub-Saharan African Countries Presented by: Anya Shen Viviane D. Lima, Wendy Zhang,
Doing the Right Thing Karen A. Stanecki XV International AIDS Conference.
Is HIV/AIDS still exceptional? Alan Whiteside Health Economics and HIV/AIDS Research Division, University of KwaZulu-Natal Durban Presentation to Daniel.
Access to ARVs : good news bad news David Henry WHO Collaborating Centre for Rational Use of Drugs The University of Newcastle NSW.
Higher antiretroviral treatment coverage is associated with lower HIV infection rates: analysis of 51 low and middle-income countries Andrew Hill, Liverpool.
Moving to the final chapter of the AIDS epidemic.
AIDS/Other Diseases Sub-Saharan Africa.
World Bank, October 5, 2005 Tackling TB in the HIV era: implications for policy dialogue and operations Paul Nunn 5 October 2005.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
Comparing HIV and AIDS Prevalence within Countries By: Dan Evans Ida Nordestgaard Lacey McLean By: Dan Evans Ida Nordestgaard Lacey McLean 30 April 2009Economic.
Is the pricing of antiretrovirals equitable? Analysis of antiretroviral drug prices in 20 low and middle income countries Andrew Hill, Pharmacology and.
HIV Therapy for the Developing World: A Global Health Challenge Harold W. Jaffe, MD Department of Public Health University of Oxford Oxford, UK.
EG3244 Development Geographies The AIDS crisis Dr Mark Cresswell.
Global Response to HIV/AIDS Nigerian Nurses Association of USA June 30, 2006 Carolyn M Hall, MSN/MPH, ACRN Global HIV/AIDS Program U.S. Department of Health.
Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew.
Antiretroviral Treatment (ART) & Human resources Wim Van Damme Department of Public Health ITM, 17 October 2006.
Bell Ringer What conditions could lead to an atmosphere susceptible to genocide?
HIV & AIDS FUNDING AND ECONOMIC RECESSION: A CALL FOR VISIONARY LEADERSHIP International AIDS Conference Vienna, 2010 Vailet Mukotsanjera-Kowayi: HEAD:
Response of Governments/International Institutions/Civil Society on Scaling Up HIV/AIDS Financing Global Conference Brasilia, Brazil – November 2006 Aisha.
HIV/AIDS and Trade Presentation by Ngoni Chibukire SAfAIDS 17 Beveridge Road Avondale Harare Tel: /4.
Monitoring UA 2010 in health sector 1 |1 | Monitoring progress towards Universal Access 2010 in the health sector Kevin M De Cock Ties Boerma.
AIDS in Sub Saharan Africa AIDS – a virus with no known cure first identified in the Belgian Congo in It’s now a global epidemic, and poverty and.
The State of the Epidemic in 2010 by Professor Alan Whiteside HEARD House of Lords 9 th March 2010 DFID HIV Leaders Meeting.
Tobacco and China A Complex Challenge By Ayda A. Yurekli, Ph.D World Bank, Washington DC Ministerial Level Economics of Tobacco Control Seminar, Beijing,
AIDS Epidemic Update December /06 e. AIDS Epidemic Update December /06 e TOTAL North America Eastern Europe & Central Asia Latin America.
PEPFAR Investment Strategy (8 years of PEPFAR) Data source : OGAC Budget Total PEPFAR Investment: $21,285,918,291 Saving Lives : Changing the.
International Public Health Globalization and Disease in history Black death in 14th century Europe Smallpox in the Americas Great Influenza of 1918.
Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.
AFRICA HIV/AIDS AIDS DATA SOURCE: UNAIDS 2007 REPORT WORLD HEALTH ORGANIZATION.
What will it take to turn the tide? Bernhard Schwartländer Yogan Pillay Till Baernighausen.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
The Global HIV/AIDS Epidemic Jennifer Kates, M.A., M.P.A. Vice President and Director, HIV Policy Kaiser Family Foundation KaiserEDU.org Tutorial April.
Where services are needed The number of people (both adults and children) living with HIV who are not receiving antiretroviral therapy.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
AIDS 8, 493 deaths per day 3.1 million deaths per year (2004 WHO estimates) More than 90% of those infected with HIV/AIDS live in developing countries.
Abt Associates Inc. In collaboration with: I Aga Khan Foundation I Bitrán y Asociados I BRAC University I Broad Branch Associates I Deloitte Consulting,
25 Years of AIDS – The Global Response 16 August 2006 XVI International AIDS Conference Toronto.
World Vision Experiences in Making ART Treatment Affordable and Available Dr. Daniel J Malleboyina M.B.B.S, MBA, MPH Regional Advisor HIV & AIDS- Asia.
Where services are needed The number of women and girls who were newly infected with HIV in Note: For Botswana and Zimbabwe, the number of women.
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
1 06/06 e Global HIV epidemic, 1990 ‒ 2005*HIV epidemic in sub-Saharan Africa, 1985 ‒ 2005* Number of people living with HIV % HIV prevalence, adult (15-49)
Are You Smarter Than A TRU Teen? TRU Price of Tobacco and Initiation Trivia.
Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,
What Will it Take to Reach the Fast Track Prevention Targets? July 18, 2016, International AIDS Conference Karl L. Dehne, Chief Prevention, UNAIDS.
Macroeconomic effects of the response to HIV: Defining the path to long run impact analysis XVII International AIDS Conference Mexico, 5 August 2008 E.
Resource Availability for HIV, Overview of the financing situation
Somya Gupta, Reuben Granich
TB-HIV Last updated: January 2017.
27 years of responding to AIDS
deaths per year (2013 WHO estimates)
27 years of responding to AIDS
Tuberculosis (TB): The 22 High-Burden Countries (HBCs)
Global epidemiology of injecting drug use
TB-HIV Last updated: March 2018.
By: Dr Mirzaei.
World Health Organization
27 years of responding to AIDS
TB-HIV Last updated: November 2018.
Medicine in third world countries
وضعیت بیماری سل در جهان، منطقه و ایران
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
Financing South Africa’s HIV Response
Demand Forecasts for for HIV/AIDS ARV formulations
The role of tobacco price on consumption
Strategic framework for TB/HIV
Presentation transcript:

Funding Universal Access through a “Global Health Charge” on alcohol and tobacco: feasibility in the 20 countries with the largest HIV epidemics Dr Andrew Hill, Pharmacology and Therapeutics, Liverpool University, UK Dr Will Sawyer, MetaVirology Ltd, London, UK World AIDS Conference, Washington, USA, July 2012 [Abstract MOAE0306]

Thanks to: Joep LangeUniversity of Amsterdam Elly KatabiraInternational AIDS Society, Kampala Ceppy MerryInfectious Diseases Institute, Kampala Praphan PhanuphakThai Red Cross AIDS Society, Bangkok Marco VittoriaWorld Health Organization, Geneva Dave Ripin Clinton Foundation Andrew LevinClinton Foundation Chris DuncombeBill and Melinda Gates Foundation Ben PlumleyPangaea AIDS Foundation Nathan FordMedecins Sans Frontieres, Geneva

The HIV epidemic in 2011: 34.2 million infected 7 million need treatment, but have no access 8 million treated 19 million: will need ARVs in future Source: UNAIDS 2012: “Together we will end AIDS” In future, 19 million more people will need treatment 2.5 million new infections per year 1.7 million deaths per year

$7 billion per year shortfall in funding for Universal Access 1.International funding for HIV: $8.6 billion in Funding from low / middle-income countries: $8.2 billion in Additional funding required: $7 billion per year Source: UNAIDS 2012: “Together we will End AIDS”

Global Financial Crisis How can we afford to treat million people with HIV in the future?

Alcohol, tobacco, HIV/AIDS, malaria and TB as causes of death worldwide UNAIDS Epidemiology Reports 2011, WHO smoking and alcohol statistics, UN population reports Annual deaths in 2010, worldwide: Alcohol abuse: 2.5 millioncould be prevented by cutting Tobacco: 6 million (->8 million)consumption HIV/AIDS: 1.8 millioncould be prevented by better TB: 1.1 milliontreatment and care Malaria: million Alcohol and tobacco are under-taxed in low and middle income countries; consumption is growing. Increasing tax on alcohol and tobacco is known to improve public health.

Taxes on tobacco and alcohol are low in many African countries World Health Organization standard: taxes should be at least 70% of the retail price of a packet of cigarettes 1 High income countries: 38/48 (79%) have a tax rate of at least 50% Low-income countries: 11/36 (31%) have a tax rate of at least 50% Packet of 20 cigarettes in UK and Kenya: in UK = $11 Excise Tax + VAT = $9 80% in Kenya 2 = $1 Excise Tax + VAT = $ % Ref 1: WHO report on global tobacco epidemic 2011 Ref 2:

Global Health Charge Middle and low income countries introduce a small extra “Global Health Charge” on alcohol and tobacco: 1 US cent per 10mL unit of unit of alcohol 10 US cents per packet of 20 cigarettes

Global Health Charge is collected by National Governments, from the main alcohol and tobacco suppliers, when supplies are sent out from their breweries and factories. This money is collected and spent only at the National level, to fund access to HIV, TB and malaria treatment and care. Money can be used in partnership with Global Fund, PEPFAR and NGOs to jointly fund treatment access programmes. Global Health Charge – how would it work?

Global Health Charge: calculations by country UNAIDS Epidemiology Reports 2011, WHO smoking and alcohol statistics, UN population reports Take the 20 countries with the largest HIV epidemics Annual alcohol and tobacco consumption: commercial (recorded) supplies Adult population size Number of patients who need antiretroviral treatment by country? Cost of Universal Access calculated assuming 2011 costs of treatment, medical care and diagnostics ($861 per patient/year of treatment). In each country, could the “Global Health Charge” fund Universal Access, and what money could be left over to pay for TB, Malaria and other health priorities?

Global Health Charge: calculations by country UNAIDS Epidemiology Reports 2011, WHO smoking and alcohol statistics, UN population reports Costs per person-year on antiretroviral treatment: $861 Antiretroviral treatment: $416 (73% 1 st line, 20% 2 nd line, 7% 3 rd line) Including importation and transport / storage. Diagnostics: $145 (2 x HIV RNA, 2 x CD4, 5% with genotype) Medical care: $300

Results – example of Kenya Adult population size / HIV: 26 million adults 1.5 to 1.6 million people HIV+, 430,000 people already on ARVs (2010 data) Alcohol consumption per person-year: 1.6 litres recorded, 2.5 unrecorded Tobacco consumption per person-year: 8.4 packs of 20 cigarettes Annual revenue from Global Health Charge (1c / 10c): $63 million Number of people needing antiretrovirals (2010): 277,000 Cost of Universal Access (100%): $239 million ($861 per patient) Number of people who could be treated from GHC (1c / 10c): 73,000 Global Health Charge of 5c / unit alcohol and 25c / packet of cigarettes in Kenya would fund 100% Universal Access ($260 million / year revenue)

References: UNAIDS Epidemiology Reports 2011, WHO smoking and alcohol statistics, UN population reports Annual charges and funds available in ten countries (1c / 10c rate): ___________________________________________________________________________________ CountryPatients needingGlobal healthARV access TB/malaria ARV accesscharges: valueextra costs* funds 1c / 10c charge ___________________________________________________________________________________ Nigeria 1,040,000$ 1120 m$ 896 m $ 223 m Uganda 281,000$ 259 m$ 243 m $ 16 m Botswana 35,000 $ 10 m$ 8 m $ 2 m Thailand113,000$ 446 m$ 97 m $ 348 m Vietnam 47,000$ 81 m$ 40 m $ 41 m India 825,000$ 887 m$ 710 m $ 177 m Brazil 89,000$ 1170 m$ 76 m $ 1,094 m Russia250,000$ 2165 m$ 216 m $ 1,949 m Ukraine 147,000$ 634 m$ 126 m $ 507 m China184,000$11,002 m$ 158 m $10,844 m ___________________________________________________________________________________ Total: All 3,011,000 eligible patients put on ARV treatment (total cost: $2.57 billion/year) Substantial additional funding available for HIV prevention, TB, Malaria, other diseases ___________________________________________________________________________________ *assumes $861/year cost for treatment and care, per person-year 10 countries could afford 100% Universal Access to ARVs with “Global Health Charge”

References: UNAIDS Epidemiology Reports 2011, WHO smoking and alcohol statistics, UN population reports Annual charges and funds available in ten countries (1c alcohol / 10c tobacco rate): ___________________________________________________________________________________ CountryPatients needingGlobal healthExtra patients Tax for ARV accesscharges: valueon ARV’s100% UA 1c / 10c charge 1c / 10c charge ___________________________________________________________________________________ Cameroun 140,000 $ 74 m 86,000 2c / 10c Cote d’Ivoire 125,000$ 79 m 91,000 2c / 10c DR Congo 256,000 $ 121 m140,000 2c / 10c Tanzania 351,000$ 154 m179,000 2c / 15c South Africa1,110,000$ 323 m375,000 3c / 25c Kenya 277,000$ 63 m 73,000 5c / 20c Zambia 136,000$ 24 m 28,000 5c / 25c Zimbabwe 234,000$ 39 m 45,000 5c / 25c Mozambique 331,000$ 41 m 48,000 10c / 30c Malawi 189,000$ 14 m 16,00014c / 50c ___________________________________________________________________________________ Total: 1.08/3.1million (35%) eligible patients put on ARV treatment (total cost: $931 million/year) ___________________________________________________________________________________ *assumes $861/year cost for treatment and care, per person-year 10 countries could help to pay for Universal Access with “Global Health Charge”

Limitations of the analysis 1.Calculations are based on average $861 cost per person-year for antiretroviral treatment, diagnostics and care. Analyses could be re-run with lower costs. 2. Antiretroviral drugs need to be accessible at minimum prices (CHAI/MSF) 3. Analyses based on 2010 estimates of HIV prevalence – updating needed 4. Could increased taxation of alcohol and tobacco lead to cross-border smuggling and/or increased use of non-commercial supplies? 5. Enforcement of taxation is required, including small-scale suppliers and brewers. 6. Other “sin taxes” could be planned, to cover other public health priorities – e.g. vaccination, cardiovascular disease.

Conclusions A “Global Health Charge” of US 1c per 10mL unit of alcohol and US 10c per packet of 20 cigarettes, collected and spent at the National level, could fund 100% Universal access to ARV treatment in 10 of the 20 countries with the largest HIV epidemics (3 million additional people on ARV treatment). In these countries, substantial additional funds would be available to treat malaria, TB and other health priorities. In the other 10 countries, 1.1 million people could be put on ARV treatment with a 1c / 10c Global Health Charge. Higher charges could allow 100% Universal Access in these countries (e.g. 5c / 20c in Kenya). Increased taxation could lower consumption of alcohol and tobacco, with associated public health benefits